Summary

The global market for Artificial Blood Substitute was estimated to be worth US$ 11.73 million in 2024 and is forecast to a readjusted size of US$ 39.78 million by 2031 with a CAGR of 18.77% during the forecast period 2025-2031.
The global key companies of Artificial Blood Substitute include Perftoran, HbO2 Therapeutics, Hemarina, Aurum Biosciences Ltd., KaloCyte Inc., Prolong Pharmaceuticals, NuvOx Pharma, etc. In 2024, the global two largest players hold a share approximately 92% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Artificial Blood Substitute, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Artificial Blood Substitute by region & country, by Type, and by Application.
The Artificial Blood Substitute market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Blood Substitute.

Market Segmentation
By Company
 Perftoran
 HbO2 Therapeutics
 Hemarina
 Aurum Biosciences Ltd.
 KaloCyte Inc.
 Prolong Pharmaceuticals
 NuvOx Pharma

Segment by Type
 Perfluorocarbon-based Oxygen Carrier (PFC)
 Hemoglobin-based Oxygen Carrier (HBOC)

Segment by Application
 Military
 Civil

By Region
 North America
 Europe
 China
 Japan

Consumption by Region
 North America
 United States
 Canada
 Asia-Pacific
 China
 Japan
 Southeast Asia
 India
 Rest of Asia-Pacific
 Europe
 Russia
 Germany
 France
 U.K.
 Italy
 Rest of Europe
 Latin America, Middle East & Africa
 South Africa
 Rest of Latin America, Middle East & Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Artificial Blood Substitute company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Artificial Blood Substitute in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Artificial Blood Substitute in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview 1
1.1 Artificial Blood Substitute Product Introduction 1
1.2 Global Artificial Blood Substitute Market Size Forecast (2020-2031) 2
1.3 Artificial Blood Substitute Market Trends & Drivers 4
1.3.1 Artificial Blood Substitute Industry Trends 4
1.3.2 Artificial Blood Substitute Market Drivers & Opportunity 5
1.3.3 Artificial Blood Substitute Market Challenges 6
1.3.4 Artificial Blood Substitute Market Restraints 7
1.4 Assumptions and Limitations 7
1.5 Study Objectives 8
1.6 Years Considered 9
2 Competitive Analysis by Company 10
2.1 Global Artificial Blood Substitute Players Revenue Ranking (2024) 10
2.2 Global Artificial Blood Substitute Revenue by Company (2020-2025) 10
2.3 Key Companies Artificial Blood Substitute Manufacturing Base Distribution and Headquarters 11
2.4 Key Companies Artificial Blood Substitute Product Offered 12
2.5 Key Artificial Blood Substitute Companies Established Year 12
2.6 Artificial Blood Substitute Market Competitive Analysis 13
2.6.1 Artificial Blood Substitute Market Concentration Rate (2020-2025) 13
2.6.2 Global 2 Largest Companies by Artificial Blood Substitute Revenue in 2024 14
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Artificial Blood Substitute as of 2024) 15
2.7 Mergers & Acquisitions, Expansion 16
3 Segmentation by Type 18
3.1 Introduction by Type 18
3.1.1 Perfluorocarbon-based Oxygen Carrier (PFC) 18
3.1.2 Hemoglobin-based Oxygen Carrier (HBOC) 19
3.2 Global Artificial Blood Substitute Sales Value by Type 19
3.2.1 Global Artificial Blood Substitute Sales Value by Type (2020 VS 2024 VS 2031) 20
3.2.2 Global Artificial Blood Substitute Sales Value, by Type (2020-2031) 22
3.2.3 Global Artificial Blood Substitute Sales Value, by Type (%) (2020-2031) 22
4 Segmentation by Application 24
4.1 Introduction by Application 24
4.1.1 Military 24
4.1.2 Civil 25
4.2 Global Artificial Blood Substitute Sales Value by Application 25
4.2.1 Global Artificial Blood Substitute Sales Value by Application (2020 VS 2024 VS 2031) 26
4.2.2 Global Artificial Blood Substitute Sales Value, by Application (2020-2031) 28
4.2.3 Global Artificial Blood Substitute Sales Value, by Application (%) (2020-2031) 28
5 Segmentation by Region 30
5.1 Global Artificial Blood Substitute Sales Value by Region 30
5.1.1 Global Artificial Blood Substitute Sales Value by Region: 2020 VS 2024 VS 2031 30
5.1.2 Global Artificial Blood Substitute Sales Value by Region (2020-2025) 30
5.1.3 Global Artificial Blood Substitute Sales Value by Region (2026-2031) 31
5.1.4 Global Artificial Blood Substitute Sales Value by Region (%), (2020-2031) 31
5.2 North America 33
5.2.1 North America Artificial Blood Substitute Sales Value, 2020-2031 33
5.2.2 North America Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031 34
5.2.3 North America Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031 35
5.2.4 North America Artificial Blood Substitute Sales Value by Application, 2024 VS 2031 37
5.3 Europe 39
5.3.1 Europe Artificial Blood Substitute Sales Value, 2020-2031 39
5.3.2 Europe Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031 40
5.3.3 Europe Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031 41
5.3.4 Europe Artificial Blood Substitute Sales Value by Application, 2024 VS 2031 43
5.4 Asia Pacific 45
5.4.1 Asia Pacific Artificial Blood Substitute Sales Value, 2020-2031 45
5.4.2 Asia Pacific Artificial Blood Substitute Sales Value by Region (%), 2024 VS 2031 46
5.4.3 Asia Pacific Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031 47
5.4.4 Asia Pacific Artificial Blood Substitute Sales Value by Application, 2024 VS 2031 49
5.5 Latin America, Middle East & Africa 51
5.5.1 Latin America, Middle East & Africa Artificial Blood Substitute Sales Value, 2020-2031 51
5.5.2 Latin America, Middle East & Africa Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031 52
5.5.3 Latin America, Middle East & Africa Artificial Blood Substitute Sales Value by Application, 2024 VS 2031 53
5.5.4 Latin America, Middle East & Africa Artificial Blood Substitute Sales Value by Application, 2024 VS 2031 55
6 Segmentation by Key Countries/Regions 57
6.1 Key Countries/Regions Artificial Blood Substitute Sales Value Growth Trends, 2020 VS 2024 VS 2031 57
6.2 Key Countries/Regions Artificial Blood Substitute Sales Value, 2020-2031 58
6.3 United States 61
6.4 Europe 62
6.5 China 63
6.6 Japan 64
6.7 South Africa 65
6.8 Southeast Asia 66
6.9 India 67
7 Company Profiles 68
7.1 Perftoran 68
7.1.1 Perftoran Profile 68
7.1.2 Perftoran Main Business 69
7.1.3 Perftoran Artificial Blood Substitute Products, Services and Solutions 69
7.1.4 Perftoran Artificial Blood Substitute Revenue (US$ Million) & (2020-2025) 70
7.2 HbO2 Therapeutics 71
7.2.1 HbO2 Therapeutics Profile 71
7.2.2 HbO2 Therapeutics Main Business 71
7.2.3 HbO2 Therapeutics Artificial Blood Substitute Products, Services and Solutions 72
7.2.4 HbO2 Therapeutics Artificial Blood Substitute Revenue (US$ Million) & (2020-2025) 73
7.2.5 HbO2 Therapeutics Recent Developments 74
7.3 Hemarina 74
7.3.1 Hemarina Profile 74
7.3.2 Hemarina Main Business 75
7.3.3 Hemarina Artificial Blood Substitute Products, Services and Solutions 75
7.3.4 Hemarina Recent Developments 77
7.4 Aurum Biosciences Ltd. 77
7.4.1 Aurum Biosciences Ltd. Profile 78
7.4.2 Aurum Biosciences Ltd. Main Business 78
7.4.3 Aurum Biosciences Ltd. Artificial Blood Substitute Products, Services and Solutions 79
7.4.4 Aurum Biosciences Ltd. Recent Developments 79
7.5 KaloCyte Inc. 80
7.5.1 KaloCyte Inc. Profile 80
7.5.2 KaloCyte Inc. Main Business 80
7.5.3 KaloCyte Inc. Artificial Blood Substitute Products, Services and Solutions 81
7.5.4 KaloCyte Inc. Recent Developments 82
7.6 Prolong Pharmaceuticals 82
7.6.1 Prolong Pharmaceuticals Profile 82
7.6.2 Prolong Pharmaceuticals Main Business 83
7.6.3 Prolong Pharmaceuticals Artificial Blood Substitute Products, Services and Solutions 84
7.6.4 Prolong Pharmaceuticals Recent Developments 84
7.7 NuvOx Pharma 85
7.7.1 NuvOx Pharma Profile 85
7.7.2 NuvOx Pharma Main Business 86
7.7.3 NuvOx Pharma Artificial Blood Substitute Products, Services and Solutions 86
7.7.4 NuvOx Pharma Recent Developments 87
8 Industry Chain Analysis 89
8.1 Artificial Blood Substitute Industrial Chain 89
8.2 Artificial Blood Substitute Upstream Analysis 89
8.2.1 Key Raw Materials 90
8.2.2 Raw Materials Key Suppliers 90
8.2.3 Manufacturing Cost Structure 91
8.3 Midstream Analysis 92
8.4 Downstream Analysis (Customers Analysis) 92
8.5 Sales Model and Sales Channels 93
8.5.1 Artificial Blood Substitute Sales Model 93
8.5.2 Sales Channel 94
8.5.3 Artificial Blood Substitute Distributors 94
9 Research Findings and Conclusion 95
10 Appendix 97
10.1 Research Methodology 97
10.1.1 Methodology/Research Approach 97
10.1.2 Data Source 100
10.2 Author Details 103
10.3 Disclaimer 104